Plain-English translation of NCT07416552 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called CEA-PRIT 2.0, which uses radioactive lead combined with special antibodies to target and attack colorectal cancer cells. The study will measure how safe the treatment is, how well it works, and what dose works best. It's designed for people whose cancer has continued to grow despite standard chemotherapy and other available treatments.
Most people with advanced colorectal cancer eventually stop responding to current standard treatments, leaving few options. This medication uses a newer approach—combining radiation with antibodies that seek out cancer cells—to give patients a potentially more effective choice when other treatments have stopped working.
The study is divided into three parts. In the first part, you'll receive intravenous injections of special antibodies combined with radioactive material over about 28-day cycles, and imaging scans will measure how the treatment travels through your body. In the second part, researchers will test different doses of the radioactive component to find the safest effective amount. In the third part, more participants will receive the treatment at the dose level determined to be best. Overall, you may receive up to 6 cycles of treatment (about 6 months), with regular visits for infusions, blood tests, and imaging scans to monitor how well the treatment is working and watch for any side effects.
AI-generated summary from trial data · Jul 8, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
Hoffmann-La Roche
Enrollment target
~180 participants
Started
July 2026
Primary completion
February 2034
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Reference Study ID Number: BP45930 https://forpatients.roche.com/ No attachments to email below.
Hoffmann-La Roche
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.